welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Solid Biosciences Reports First Quarter 2019 Financial Results and Provides Business Update


Solid Biosciences Inc. (Nasdaq: SLDB) today reported financial results for the first quarter ended March 31, 2019 and provided a business update.

“We have continued to advance our programs for Duchenne muscular dystrophy over the last few months, particularly our lead microdystrophin gene therapy candidate, SGT-001. Building on our findings from the preliminary Phase I/II clinical data that we announced in February, we initiated dosing at 2E14 vg/kg in the second cohort of patients,” said Ilan Ganot, Chief Executive Officer, President and Co-Founder of Solid Biosciences. “Now, we are working to progress as quickly as possible, and we look forward to providing additional data later this year.”

Solid Biosciences Reports First Quarter 2019 Financial Results And Provides Business Update